Twelve months ago, the Board set itself three key milestone targets to achieve in 2018, and I am very pleased to report that all three have been achieved this year. These are:
1. Receiving the full GMP certification and manufacturing license of our European Medical Cannabis Manufacturing Facility;
2. Gaining St Vincent’s Ethics Committee and then TGA Approval for authorised prescribers of CannEpilTM in Australia; and
3. Securing a licenceto build and operate a commercial scale medical cannabis facility in Europe for the production of GMP flowers and GMP pharma grade medicine.
Malta?
MXC Price at posting:
4.4¢ Sentiment: None Disclosure: Held
